Webster Lynn R, Grabois Martin
PRA Health Sciences, 3838 South 700 East, Suite 202, Salt Lake City, UT 84106.
Baylor College of Medicine, Houston, TX.
PM R. 2015 Nov;7(11 Suppl):S236-S247. doi: 10.1016/j.pmrj.2015.08.011.
It is the responsibility of medical professionals to do all that is possible to safely alleviate pain. Opioids are frequently prescribed for pain but are associated with the potential for misuse, addiction, diversion, and overdose mortality, and thus they are strictly regulated. To adhere to legitimate practice standards, physicians and other health care providers who prescribe opioids for pain, particularly on a long-term basis, need current information on federal and state laws, treatment guidelines, and regulatory actions aimed at reducing opioid-related harm. The number of opioid-prescribing policies is increasing as federal and state governments increase scrutiny to alleviate opioid-related problems in society. Failure to adequately comply with opioid-prescribing laws and policies may put a prescriber at risk for legal or regulatory sanctions. Necessary actions include thorough documentation of prescribing decisions and assessment and follow-up of patient risk for opioid misuse or addiction. Tools to check for patient adherence to the prescribed regimen include prescription monitoring databases and urine drug screening. This article presents an overview of the legal and regulatory framework surrounding controlled substances law. It further discusses recent actions at the federal and state level to prevent opioid-related harm.
医疗专业人员有责任尽一切可能安全地减轻疼痛。阿片类药物常用于止痛,但存在滥用、成瘾、转移和过量致死的风险,因此受到严格监管。为了遵守合法的执业标准,为疼痛开具阿片类药物的医生和其他医疗服务提供者,尤其是长期开具此类药物的人员,需要了解有关旨在减少阿片类药物相关危害的联邦和州法律、治疗指南及监管行动的最新信息。随着联邦和州政府加强审查以缓解社会上与阿片类药物相关的问题,阿片类药物处方政策的数量在不断增加。未能充分遵守阿片类药物处方法律和政策可能会使开处方者面临法律或监管制裁的风险。必要的行动包括对处方决定进行全面记录,以及对患者阿片类药物滥用或成瘾风险进行评估和随访。检查患者是否遵守规定治疗方案的工具包括处方监测数据库和尿液药物筛查。本文概述了围绕受控物质法的法律和监管框架。它还进一步讨论了联邦和州层面为预防阿片类药物相关危害而采取的近期行动。